Telbivudine (Tyzeka) for Chronic Hepatitis B
The FDA has approved the nucleoside analog telbivudine (Tyzeka - Novartis/Idenix) for treatment of patients >e;16 years old with active chronic hepatitis B virus (HBV) infection. It is the fourth oral drug marketed for this indication in the US....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Telbivudine (Tyzeka) for Chronic Hepatitis B
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1253
Article Code: 1253b
Date: January 29, 2007
Volume: 49
Pages: 11-12
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1253
Article Code: 1253b
Date: January 29, 2007
Volume: 49
Pages: 11-12
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
